MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rogers, M. J.
Right arrow Articles by Ebetino, F. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rogers, M. J.
Right arrow Articles by Ebetino, F. H.

Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae

MJ Rogers, X Xiong, RJ Brown, DJ Watts, RG Russell, AV Bayless and FH Ebetino

Krebs Institute, Department of Molecular Biology and Biotechnology, University of Sheffield, UK.

The mechanisms by which bisphosphonate drugs inhibit osteoclast- mediated bone resorption are unclear. Effects of bisphosphonates on cellular enzymes, metabolic pathways, and osteoclast morphology have previously been described and could culminate in a generalized cytotoxic effect or a decreased capacity of osteoclasts to resorb bone. Recent studies of the structure-activity relationship for the bisphosphonate side chain indicate, however, that at least the newer generations of nitrogen-containing bisphosphonates probably act by binding to a specific target at a site that is complementary in structure to the bisphosphonate side chain. We have previously proposed that such a target for bisphosphonates is also present in amoebae of the cellular slime mold Dictyostelium discoideum, because growth of this microorganism is inhibited by a wide range of bisphosphonates in a manner that closely reflects the antiresorptive potencies of the bisphosphonates in vivo. We have added support for this view by examining the potency towards Dictyostelium of bisphosphonates in which slight changes in the structure of the side chain or conformational restrictions to the side chain have marked effects on antiresorptive potency. The changes in the side chain that affected the in vivo antiresorptive potency of the bisphosphonates consistently affected in a similar manner the potency of the bisphosphonates as inhibitors of the growth of Dictyostelium amoebae. These observations confirm that bisphosphonate drugs have a molecular target that is common to both Dictyostelium amoebae and osteoclasts.

Volume 47, Issue 2, pp. 398-402, 02/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
PediatricsHome page
R. G. G. Russell
Bisphosphonates: Mode of Action and Pharmacology
Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162.
[Abstract] [Full Text] [PDF]


Home page
Eukaryot CellHome page
A. Ortiz-Gomez, C. Jimenez, A. M. Estevez, J. Carrero-Lerida, L. M. Ruiz-Perez, and D. Gonzalez-Pacanowska
Farnesyl Diphosphate Synthase Is a Cytosolic Enzyme in Leishmania major Promastigotes and Its Overexpression Confers Resistance to Risedronate.
Eukaryot. Cell, July 1, 2006; 5(7): 1057 - 1064.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. E. Dunford, K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, and M. J. Rogers
Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 235 - 242.
[Abstract] [Full Text]


Home page
ScienceHome page
G. Mundy, R. Garrett, S. Harris, J. Chan, D. Chen, G. Rossini, B. Boyce, M. Zhao, and G. Gutierrez
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Science, December 3, 1999; 286(5446): 1946 - 1949.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
H. L. Benford, J. C. Frith, S. Auriola, J. Mönkkönen, and M. J. Rogers
Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmacological Classes of Bisphosphonate Drugs
Mol. Pharmacol., July 1, 1999; 56(1): 131 - 140.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. E. Fisher, M. J. Rogers, J. M. Halasy, S. P. Luckman, D. E. Hughes, P. J. Masarachia, G. Wesolowski, R. G. G. Russell, G. A. Rodan, and A. A. Reszka
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
PNAS, January 5, 1999; 96(1): 133 - 138.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. Fleisch
Bisphosphonates: Mechanisms of Action
Endocr. Rev., February 1, 1998; 19(1): 80 - 100.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics